VRise Therapeutics is a precision oncology company dedicated to the discovery and development of novel small molecules aimed at targeting critical pathways involved in cancer growth, proliferation, and differentiation. The company employs a proprietary discovery engine that integrates cutting-edge technologies and a lean development methodology, leveraging global research resources across India, the UK, and the US. This innovative approach has led to the identification of a diverse portfolio of promising therapeutics, including inhibitors targeting specific KRAS mutations associated with various cancers, such as colorectal, lung, and pancreatic cancers.

In addition to its focus on KRAS mutations, VRise Therapeutics is exploring the DNA Damage Response (DDR) pathway, which plays a crucial role in cancer progression due to its involvement in cell cycle regulation and response to DNA damage. The company emphasizes the importance of biomarker-driven targets and aims to incorporate companion diagnostics into its development process, thereby enhancing the precision of its therapies. By engaging with new research areas and fostering strategic collaborations, VRise is committed to advancing the next generation of targeted cancer therapies that address significant unmet medical needs.

United States

VRise Therapeutics is a global biotechnology company, which aspires to bring transformative change to the lives of cancer patients, through precision medicine.

Cancer

Digestive System Diseases

Endocrine System Diseases

Urogenital Diseases

VRise Therapeutics

Colorectal cancer

Non-small cell lung carcinoma

VRTX126

Small Molecule Pharmaceuticals

Pancreatic cancer

VRTX153

Castration-resistant prostate cancer

Androgen Receptor Degrader (PROTAC) Program

Solid tumor/s

SOS1: Downstream Expansion; RAS Expansion Program

Massachusetts

Therapeutic

VRise Therapeutics

Company Details